Patients with non-resectable advanced or recurrent NSCLC receiving treatment with nivolumab
Conditions
Interventions
None listed
Sponsors
Osaka Medical Center for Cancer and Cardiovascular
National Hospital Organization Kinki Chuo Chest Medical Center Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with a definite diagnosis of NSCLC based on histology or cytology. 2) Patients unsuitable for curative radiation therapy who have a clinical diagnosis of either recurrent disease or stage IV NSCLC. 3) Patients who receive at least one dose of nivolumab.
Exclusion criteria
Exclusion criteria: Patients who have previously received nivolumab in a clinical trial will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate whether retrospective analysis of nivolumab therapy in the real clinical setting reproduces the RR shown by primary analysis of the CheckMate trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| A: Relation between pretreatment patient characteristics and the efficacy of nivolumab and its ARs. B: Response patterns, sites of response (anatomical regions), and ARs C: Influence of nivolumab on subsequent treatment D: Correlation with effect of nivolumab and IHC of PD-L1 | — |
Countries
Japan
Contacts
Public ContactMotohiro Tamiya
Osaka International Cancer Institute Thoracic Oncology
Outcome results
None listed